Key Highlights

  • Shares are trading up 19.07% today at $5.28, extending gains from last week's biosimilar licensing agreement with Lotus Pharmaceutical.
  • Bank of America initiated coverage today with a Buy rating and $7 price target, while UBS reiterated its Buy rating and $6 target.
  • The rally builds on last week's deal covering AVT34 and AVT87, biosimilar candidates to durvalumab and emicizumab, with potential value to Alvotech of up to approximately $150 million in upfront and milestone payments.
  • Investors are also focused on AVT05, where management remains confident in a Q4 launch, and on Q4 approval and launch timelines that remain intact following a recent FDA inspection closure.

Why Is Alvotech Stock Up Today?

Alvotech (NASDAQ:ALVO) shares are trading up 19.07% today at $5.28, as fresh bullish analyst coverage compounds momentum from last week's biosimilar licensing agreement with Lotus Pharmaceutical. The move builds on a stock that has already been trending higher over the past several sessions.

Alvotech is a global, pure-play biopharmaceutical company dedicated to the development, manufacture, and commercialization of biosimilar medicines, headquartered in Luxembourg with major operations in Reykjavik, Iceland. Founded in 2013 by Robert Wessman, the company targets key therapeutic areas including autoimmune and inflammatory diseases, ophthalmic disorders, bone diseases, and oncology. Its portfolio includes commercialized Biosimilars such as AVT02 (Humira), AVT04 (Stelara), and AVT06 (Eylea), alongside a robust pipeline featuring AVT03, AVT05, AVT16, AVT23, and AVT33, and the company partners with major global and regional pharmaceutical companies, including Teva, STADA, and JAMP Pharma, to commercialize biosimilars across developed and emerging markets.

Analysts Turn Bullish as Lotus Deal Adds Momentum

Bank of America initiated coverage on Alvotech today with a Buy rating and a $7 price target, while UBS reiterated its own Buy rating and a $6 target, noting that the company's Q4 approval and launch timelines remain intact following the recent closure of an FDA inspection. Both moves come on the heels of last week's licensing and commercialization agreement with Lotus Pharmaceutical, covering AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab). Imfinzi generated approximately $6.1 billion in global sales in 2025, and Hemlibra generated roughly $5.8 billion, underscoring the scale of the addressable markets tied to the deal.

Under the agreement, Alvotech retains rights to commercialize both products directly in the United States alongside Lotus, which will sell through its Alvogen subsidiary, while Alvotech remains the exclusive supplier for all markets and keeps responsibility for development and US regulatory approvals. Lotus separately gains exclusive commercialization rights across eight Asian markets, including South Korea, Taiwan, and Singapore. The deal carries potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing Supply revenue.

Pipeline Confidence and Litigation Remain in Focus

Investors are also watching AVT05, where management has expressed confidence in a fourth-quarter US launch, and ongoing litigation with Johnson & Johnson that continues to weigh on sentiment around the pipeline. UBS noted that while the company's second-quarter results were largely in line with expectations, the stock's positive reaction today is being driven more by the reaffirmed regulatory timelines and the structural shift in Alvotech's commercial strategy than by near-term financial results.

What This Means for Investors

Today's rally reflects two reinforcing catalysts rather than a single event: a licensing deal that expands Alvotech's addressable pipeline into oncology and rare disease markets while letting the company retain more commercial upside than its prior partnership-heavy model, and fresh analyst validation that Alvotech's regulatory and launch timelines remain on track despite past inspection-related uncertainty. The CEO's framing of the Lotus deal as a strategic evolution, allowing direct US commercialization for the first time, suggests the company is deliberately shifting toward capturing more value from its biosimilar development platform rather than relying solely on partner-led commercialization. With Q4 approval and launch catalysts still ahead for existing pipeline assets, the stock's next moves will likely hinge on whether those regulatory milestones are met on schedule.